Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor

Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage of isoniazid resistance is linked to mutations in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Hoyos, María, Perez-Herran, Esther, Gulten, Gulcin, Encinas, Lourdes, Álvarez-Gómez, Daniel, Alvarez, Emilio, Ferrer-Bazaga, Santiago, García-Pérez, Adolfo, Ortega, Fátima, Angulo-Barturen, Iñigo, Rullas-Trincado, Joaquin, Blanco Ruano, Delia, Torres, Pedro, Castañeda, Pablo, Huss, Sophie, Fernández Menéndez, Raquel, González del Valle, Silvia, Ballell, Lluis, Barros, David, Modha, Sundip, Dhar, Neeraj, Signorino-Gelo, François, McKinney, John D., García-Bustos, Jose Francisco, Lavandera, Jose Luis, Sacchettini, James C., Jimenez, M. Soledad, Martín-Casabona, Nuria, Castro-Pichel, Julia, Mendoza-Losana, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919555/
https://www.ncbi.nlm.nih.gov/pubmed/27428438
http://dx.doi.org/10.1016/j.ebiom.2016.05.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919555/
https://www.ncbi.nlm.nih.gov/pubmed/27428438
http://dx.doi.org/10.1016/j.ebiom.2016.05.006

Ejemplares similares